Related references
Note: Only part of the references are listed.Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Activated B Cells and Plasma Cells Are Resistant to Radiation Therapy
Ida Franiak-Pietryga et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
Fernanda G. Herrera et al.
CANCER DISCOVERY (2022)
Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Bradford A. Perez et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Sean McBride et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy
Yu-Hung Lee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
IgA transcytosis and antigen recognition govern ovarian cancer immunity
Subir Biswas et al.
NATURE (2021)
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee et al.
LANCET ONCOLOGY (2021)
Biomarkers of Radiotherapy-Induced Immunogenic Cell Death
Rianne D. W. Vaes et al.
CELLS (2021)
Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer
Christiane S. Eberhardt et al.
NATURE (2021)
Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy
Florent Amatore et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Rita Cabrita et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Sangwoo S. Kim et al.
CLINICAL CANCER RESEARCH (2020)
The Promise of Combining Radiation Therapy With Immunotherapy
Justin C. Jagodinsky et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Radiotherapy Cooperates with IL15 to Induce Antitumor Immune Responses
Karsten A. Pilones et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells
Patrick Innamarato et al.
JOURNAL OF IMMUNOLOGY (2020)
T-cell agonists in cancer immunotherapy
Yeonjoo Choi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
Ugur Eskiocak et al.
JCI INSIGHT (2020)
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
Maria E. Rodriguez-Ruiz et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
Xinyue Qi et al.
NATURE COMMUNICATIONS (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Tumor-reprogrammed resident T cells resist radiation to control tumors
Ainhoa Arina et al.
NATURE COMMUNICATIONS (2019)
A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Clinical Development of PD-1 in Advanced Melanoma
Rodrigo Ramella Munhoz et al.
CANCER JOURNAL (2018)
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model
Sharareh Niknam et al.
CLINICAL CANCER RESEARCH (2018)
Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer
Alison Claire Tree et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses
Ashley V. Menk et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs
Julie M. Diamond et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Mitochondria! Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation
Alvaro Teijeira et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Sarah L. Buchan et al.
IMMUNITY (2018)
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa et al.
NATURE REVIEWS CANCER (2018)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H. Segal et al.
CLINICAL CANCER RESEARCH (2017)
Host STING-dependent MDSC mobilization drives extrinsic radiation resistance
Hua Liang et al.
NATURE COMMUNICATIONS (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
4-1BB (CD137) and radiation therapy: A case report and literature review
Jay C. Shiao et al.
ADVANCES IN RADIATION ONCOLOGY (2017)
Systematic review of case reports on the abscopal effect
Yazan Abuodeh et al.
CURRENT PROBLEMS IN CANCER (2016)
Rationale for anti-OX40 cancer immunotherapy
Sandrine Aspeslagh et al.
EUROPEAN JOURNAL OF CANCER (2016)
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi et al.
LANCET ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
James Larkin et al.
JAMA ONCOLOGY (2015)
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
Andrew B. Sharabi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
Liufu Deng et al.
IMMUNITY (2014)
Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
Zineb Belcaid et al.
PLOS ONE (2014)
CD137 Promotes Proliferation and Survival of Human B Cells
Xiaoyu Zhang et al.
JOURNAL OF IMMUNOLOGY (2010)
Dendritic Cells and Stat3 Are Essential for CD137-Induced CD8 T Cell Activation-Induced Cell Death
Benyue Zhang et al.
JOURNAL OF IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
Youjin Lee et al.
BLOOD (2009)
Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti-CTLA-4 Antibody
M. Zahidunnabi Dewan et al.
CLINICAL CANCER RESEARCH (2009)
Requirement of B Cells for Generating CD4+ T Cell Memory
Jason K. Whitmire et al.
JOURNAL OF IMMUNOLOGY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells
Satoko Matsumura et al.
JOURNAL OF IMMUNOLOGY (2008)
Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain
HM Finney et al.
JOURNAL OF IMMUNOLOGY (2004)
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells
T Futagawa et al.
INTERNATIONAL IMMUNOLOGY (2002)
4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy
JL Cannons et al.
JOURNAL OF IMMUNOLOGY (2001)
Tumours can act as adjuvants for humoral immunity
DM Brown et al.
IMMUNOLOGY (2001)
Share Paper
